HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): William A. Baumgartner Timothy J. Gardner Bruce A. Reitz Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baumgartner, W. A. Articles by Reitz, B. A. Search for Related Content PubMed PubMed Citation Articles by Baumgartner, W. A. Articles by Reitz, B. A.

Ann Thorac Surg 1987;43:585-590
© 1987 The Society of Thoracic Surgeons

---

Articles

Present Expectations in Cardiac Transplantation

From the Johns Hopkins Medical Institutions, Baltimore, MD

^* Address reprint requests to Dr. Baumgartner, Department of Surgery, Blalock 618, The Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21205

The clinical introduction of cyclosporine has resulted in increased enthusiasm for cardiac transplantation. Since July, 1983, 61 patients (50 male and 11 female) have undergone orthotopic cardiac transplantation for cardiomyopathy (48 patients), ischemic heart disease (11), or congenital heart disease (2). Mean age was 39 years (range, 1.5 to 57 years). Median hospital stay was 26 days (range, 4 to 60 days). Maintenance immunosuppression consisted primarily of prednisone and cyclosporine; it was modified in 9 patients because of a pre-existing clinical condition. The incidence of rejection was 0.44 episode/patient-month within 3 months of cardiac transplantation and 0.10 episode/patient-month subsequently. The incidence of infection was 0.05 episode/patient-month. Major side effects of cyclosporine included renal dysfunction (63%) and hypertension (61%). No recipient required dialysis for renal dysfunction. Ten patients died (rejection, 4; infection, 3; carcinoma, 1; lymphoma, 1; and pulmonary hemorrhage, 1); actuarial survival at 1 and 2 years was 84 ± 6% and 76 ± 8%, respectively. Patient follow-up (cumulative, 719 patient-months) revealed that 96% of recipients were rehabilitated and 50% had returned to work. With increasing understanding of cyclosporine immunosuppression, recipients can continue to look forward to an extended life with nearly complete rehabilitation.

This article has been cited by other articles:

				P. S. Greene, D. E. Cameron, S. Augustine, T. J. Gardner, B. A. Reitz, and W. A. Baumgartner Exploratory analysis of time-dependent risk for infection, rejection, and death after cardiac transplantation Ann. Thorac. Surg., May 1, 1989; 47(5): 650 - 654. [Abstract] [PDF]

				P. M. Portner, P. E. Oyer, D. G. Pennington, W. A. Baumgartner, B. P. Griffith, W. R. Frist, D. J. Magilligan Jr, G. P. Noon, N. Ramasamy, P. J. Miller, et al. Implantable electrical left ventricular assist systems: Bridge to transplantation and future Ann. Thorac. Surg., January 1, 1989; 47(1): 142 - 150. [Abstract] [PDF]